SIONNA THERAPEUTICS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
SIONNA THERAPEUTICS, INC. (SION) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$364.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$364.00K.
- SIONNA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$624.00K.
- SIONNA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $120.00K.
- SIONNA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $237.00K, a 74.49% decline year-over-year.
- SIONNA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $172.00K, a 53.26% decline from fiscal 2024.
- SIONNA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $368.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$364.00K 10-Q · filed 2026-08-06 | -$988.00K 10-Q · filed 2026-08-06 | -$868.00K derived: sum of 3 quarters · filed 2026-08-06 | -$631.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$624.00K 10-Q · filed 2026-05-12 | -$504.00K derived: sum of 2 quarters · filed 2026-05-12 | -$267.00K derived: sum of 3 quarters · filed 2026-05-12 | -$385.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $357.00K derived: sum of 2 quarters · filed 2026-03-02 | $239.00K derived: sum of 3 quarters · filed 2026-08-06 | $172.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $237.00K 10-Q · filed 2025-11-05 | $119.00K derived: sum of 2 quarters · filed 2026-08-06 | $52.00K 10-Q · filed 2025-11-05 | -$353.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$118.00K 10-Q · filed 2026-08-06 | -$185.00K 10-Q · filed 2026-08-06 | -$590.00K derived: sum of 3 quarters · filed 2026-08-06 | $339.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$67.00K 10-Q · filed 2026-05-12 | -$472.00K derived: sum of 2 quarters · filed 2026-05-12 | $457.00K derived: sum of 3 quarters · filed 2026-05-12 | $309.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $524.00K derived: sum of 2 quarters · filed 2026-03-02 | $376.00K derived: sum of 3 quarters · filed 2026-03-02 | $368.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $929.00K 10-Q · filed 2025-11-05 | $781.00K derived: sum of 2 quarters · filed 2025-11-05 | $773.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$148.00K 10-Q · filed 2025-08-11 | -$156.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$8.00K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |